ONC · All filings · Read this filing
What changed 10-Q
Item 1. Legal Proceedings
2025-11-06 compared with 2025-08-06 · 2 added, 1 removed, 23 unchanged (12% of the section changed)
10 unchanged sentences
Pharmacyclics seeks a declaration of infringement, unspecified monetary damages and other relief.
−Removed: The Company intends to vigorously defend against the claims.
On October 12, 2023, the Court entered a joint stipulation filed by the parties to stay the infringement suit pending resolution of a petition for post-grant review (“PGR”) of the ‘803 Patent with the U.S.
4 unchanged sentences
On July 17, 2025, the USPTO denied Pharmacyclics’ request.
+Added: Pharmacyclics did not appeal the USPTO’s FWD and Director Review decision.
+Added: On September 30, 2025, the parties filed a joint stipulation with the Court to dismiss the infringement suit.
AbbVie Litigation
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.